Strategic M&A Opportunities to engage post-merger integration teams given recent merger activity with Acer America Corporation, signaling potential consolidation of commercial operations, R&D partnerships, and portfolio alignment suitable for joint development or licensing conversations.

Personalized Immunotherapy Target potential customers and partners in autoimmune and neurodegenerative spaces by highlighting Opexa's T-cell based precision immunotherapy platform, exploring collaborations, licensing, or co-development deals around Tcelna or adjacent personalized therapies.

Clinical Progress Leverage ongoing Phase IIb Abili-T trial momentum and forthcoming top-line data to open discussions with clinicians, CROs, and payers about evidence generation, real-world data studies, and staged investment partnerships tied to trial milestones.

Financial Signals Position engagements around capital-efficient collaborations given mid-range revenue indicators and publicly traded status, offering options such as milestone-based funding, strategic licensing, or equity-friendly partnerships with larger biotech players seeking niche immunotherapy assets.

Technical & Digital Identify opportunities to optimize partner and investor communications through Opexa’s tech stack and digital footprint, proposing technical diligence support, data collaboration, or joint analytics initiatives to attract tech-forward stakeholders.